Áttétes emlőrák: vizsgálatok itt: Dél-Korea
42 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleOpen-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 392 worldwide
- Run by
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00 - 1/2. fázisTaking peopleA Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Where
- Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07701941 · EU 2024-517541-14-00 - 3. fázisTaking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Busan, Daegu, Goyang-si, Seongnam-si, Seoul, Suwon, Yongin-si
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - 1/2. fázisTaking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Seoul
- Életkor
- 18 év to 100 év
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - No phaseTaking peopleEvaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
- Where
- Busan, Goyang, Incheon, Jinju, Ulsan
- Életkor
- 19 év and over
- People
- 414
- Run by
- Ulsan University Hospital
See details and how to joinNCT07405931 - No phaseCsak meghívásosNEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 100
- Run by
- Yeon Hee Park
See details and how to joinNCT07132749 - 2. fázisTaking peopleEribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 180
- Run by
- Seoul National University Hospital
See details and how to joinNCT05530057 - No phaseTaking peopleFDG PET-CT in Advanced Breast Cancer
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 100
- Run by
- Samsung Medical Center
See details and how to joinNCT07173868 - 2. fázisTaking peoplePrevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 40
- Run by
- Yeon Hee Park
See details and how to joinNCT06616987 - 1. fázisTaking peopleStudy of DM5167 in Patients With Advanced Solid Tumors
- Where
- Gyeonggi-do, Seoul
- Életkor
- 19 év and over
- People
- 58
- Run by
- DIGMBIO
See details and how to joinNCT07101601 - No phaseTaking peopleProspective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M)
- Where
- Seoul
- Életkor
- 19 év to 100 év
- People
- 400
- Run by
- Samsung Medical Center
See details and how to joinNCT05907681 - 2. fázisTaking peopleTrastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 141
- Run by
- Yonsei University
See details and how to joinNCT06837792 - No phaseCsak meghívásosMolecular Profiling in Young (<50 Years of Age) Patients With Metastatic Breast Cancer
- Where
- Seoul
- Életkor
- 19 év to 50 év
- People
- 200
- Run by
- Seoul National University Hospital
See details and how to joinNCT04098640 - 2. fázisTaking peopleTalazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 70
- Run by
- Seoul National University Hospital
See details and how to joinNCT04892693 - 2. fázisTaking peopleEvaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 64
- Run by
- Seoul National University Hospital
See details and how to joinNCT05536128 - 2. fázisTaking peopleComparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
- Where
- Seoul
- Életkor
- 19 év to 80 év
- People
- 202
- Run by
- Korea University Guro Hospital
See details and how to joinNCT05816655 - 2. fázisTaking peoplePALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 178
- Run by
- Samsung Medical Center
See details and how to joinNCT04819243